首页> 外国专利> Human pluripotent stem cells produced by the introduction of Oct3/4, Sox2, and Klf4 genes, along with a c-Myc gene or histone deacetylase inhibitor, into post

Human pluripotent stem cells produced by the introduction of Oct3/4, Sox2, and Klf4 genes, along with a c-Myc gene or histone deacetylase inhibitor, into post

机译:通过将Oct3 / 4,Sox2和Klf4基因与c-Myc基因或组蛋白脱乙酰基酶抑制剂一起引入人体后产生的人多能干细胞

摘要

Human pluripotent stem cells are disclosed which are established form human postnatal tissue through the introduction of Oct3/4, Sox2, and Klf4 genes, or Oct3/4, Sox2, and Klf4 genes in combination with either a c-Myc gene or a histone deacetylase inhibitor. Methods of inducing human pluripotent stem cells of the invention from an undifferentiated stem cell in human postnatal tissue are also claimed, as are stem cells of the invention for use in cell replacement therapy. Undifferentiated stem cells in which each of the genes Tert. Nanog, Oct3/4, and Sox2 has not undergone epigenetic inactivation, and which can be induced into the pluripotent stem cells of the invention, are also claimed.
机译:公开了人多能干细胞,其通过引入Oct3 / 4,Sox2和Klf4基因或与C-Myc基因或组蛋白脱乙酰基酶组合的Oct3 / 4,Sox2和Klf4基因而从人产后组织中建立。抑制剂。还要求保护从人出生后的组织中的未分化干细胞诱导本发明的人多能干细胞的方法,以及用于细胞替代疗法的本发明的干细胞。未分化的干细胞,其中每个基因均为Tert。还要求保护Nanog,Oct3 / 4和Sox2尚未发生表观遗传失活,并且可以将其诱导到本发明的多能干细胞中。

著录项

  • 公开/公告号GB2450603A

    专利类型

  • 公开/公告日2008-12-31

    原文格式PDF

  • 申请/专利权人 BAYER SCHERING PHARMA AG;

    申请/专利号GB20080010897

  • 申请日2008-06-13

  • 分类号C12N5/07;C12N5/0735;C12N5/074;C12N5/0775;C12N5/0789;C12N15/09;C12N15/85;

  • 国家 GB

  • 入库时间 2022-08-21 19:06:40

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号